BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol. 2014;2:240-246. [PMID: 26355300 DOI: 10.14218/jcth.2014.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
2 Guruprasad B, Kavitha S, Aruna Kumari B, Vijaykumar B, Sumati B, Mahua S, Appaji L, Jayshree R. Risk of hepatitis B infection in pediatric acute lymphoblastic leukemia in a tertiary care center from South India: HBV in Pediatric ALL. Pediatr Blood Cancer 2014;61:1616-9. [DOI: 10.1002/pbc.25065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
4 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res 2020;12:24-41. [PMID: 31743962 DOI: 10.4168/aair.2020.12.1.24] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
5 Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 2014;59 Suppl 5:S360-4. [PMID: 25352632 DOI: 10.1093/cid/ciu592] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
6 Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol 2016;4:143-50. [PMID: 27350944 DOI: 10.14218/JCTH.2016.00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
7 López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
8 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Fylaktou A, Daoudaki M, Dimou V, Sianou E, Papaventsis D, Mavrovouniotis I, Fouzas I, Papanikolaou V. Hepatitis B Reactivation in a Renal Transplant Patient Due to a Surface Antigen Mutant Strain: A Case Report. Transplantation Proceedings 2012;44:2773-5. [DOI: 10.1016/j.transproceed.2012.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Chiu YM, Lai MS, Chan KA. Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study. Arthritis Res Ther 2017;19:214. [PMID: 29089055 DOI: 10.1186/s13075-017-1413-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Tuna N, Karabay O. Hepatitis B reactivation and timing for prophylaxis. World J Gastroenterol 2015; 21(7): 2263-2264 [PMID: 25717269 DOI: 10.3748/wjg.v21.i7.2263] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Sjoblom M, Chtioui H, Fraga M, Stalder G, Grandoni F, Blum S. Hepatitis B reactivation during ruxolitinib treatment. Ann Hematol 2022. [PMID: 35488090 DOI: 10.1007/s00277-022-04851-6] [Reference Citation Analysis]
13 Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62:403-41. [PMID: 23871408 DOI: 10.1053/j.ajkd.2013.06.002] [Cited by in Crossref: 134] [Cited by in F6Publishing: 104] [Article Influence: 14.9] [Reference Citation Analysis]
14 Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol 2013;9:154-69. [PMID: 23338210 DOI: 10.1038/nrneph.2012.289] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
15 Gujar SA, Mulrooney-Cousins PM, Michalak TI. Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis. J Virol 2013;87:1035-48. [PMID: 23135718 DOI: 10.1128/JVI.01363-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
16 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
17 Klimko A, Toma GA, Bejinariu N, Secareanu SM, Andreiana I. Acute Kidney Injury in a Patient With Cryoglobulinemia Secondary to Hepatic Mucosa-Associated Lymphoid Tissue Lymphoma: Case Report and Literature Review. Cureus 2020;12:e10451. [PMID: 33072459 DOI: 10.7759/cureus.10451] [Reference Citation Analysis]
18 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
19 Nardis C. Latent virus reactivation risk and biological drugs: chronic inflammatory and immune-mediated disorders. Int J Immunopathol Pharmacol 2013;26:983-9. [PMID: 24355236 DOI: 10.1177/039463201302600419] [Reference Citation Analysis]
20 Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736. [PMID: 24961409 DOI: 10.1517/14656566.2014.931938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
21 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
22 Sezgin Göksu S, Bilal Ş, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5(1): 43-45 [PMID: 23383366 DOI: 10.4254/wjh.v5.i1.43] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
23 Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9691-9698 [PMID: 25110408 DOI: 10.3748/wjg.v20.i29.9691] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ly K, Smith MP, Thibodeaux Q, Beck K, Bhutani T, Liao W. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep 2019;5:624-6. [PMID: 31341942 DOI: 10.1016/j.jdcr.2019.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Iwafuchi Y, Oyama Y, Morita T, Kamimura A, Miyazaki S, Narita I. De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids. CEN Case Rep 2013;2:28-33. [PMID: 28509215 DOI: 10.1007/s13730-012-0033-2] [Reference Citation Analysis]
26 Koskinas J, Tampaki M, Doumba P, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient: Correspondence. British Journal of Dermatology 2013;168:679-80. [DOI: 10.1111/bjd.12120] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
27 Selvarajah V, Montano-loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012;36:691-707. [DOI: 10.1111/apt.12042] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
28 Davis BP, Ballas ZK. Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017;139:1445-56. [PMID: 28263774 DOI: 10.1016/j.jaci.2017.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
29 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
30 Khan ZH, Ilyas K, Ghazanfar H, Khan HH, Hussain Q, Hammad S, Munir A, Asim R. Fatal Fulminant Hepatitis from Rituximab-induced Hepatitis B Reactivation in a Patient with Follicular Lymphoma: A Case Report and a Brief Review of Literature. Cureus. 2018;10:e2257. [PMID: 29725560 DOI: 10.7759/cureus.2257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Skupsky J, Hu K. Current hepatitis B treatment guidelines and future research directions. Front Med 2014;8:145-57. [DOI: 10.1007/s11684-014-0335-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
33 Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma. World J Gastroenterol 2014; 20(17): 5165-5170 [PMID: 24803836 DOI: 10.3748/wjg.v20.i17.5165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
34 Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013;41:225-9. [DOI: 10.1007/s15010-012-0305-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
35 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 AlEnizi A, AlSaeid K, Alawadhi A, Hasan E, Husain EH, AlFadhli A, Ghanem A, Abutiban F, Ali Y, Al-Herz A, Mohammed K, Alkandari W, Aldei A, Alhajeri H, Dehrab A, Hayat S. Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases. Int J Rheumatol 2018;2018:5217461. [PMID: 29861734 DOI: 10.1155/2018/5217461] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Kim SJ, Hsu C, Song Y, Tay K, Hong X, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang K, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng W, Cheng A, Lim ST, Suh C, Kwong Y, Kim WS. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer 2013;49:3486-96. [DOI: 10.1016/j.ejca.2013.07.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 9.2] [Reference Citation Analysis]
38 Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178-186. [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
39 Nicoletta B, Alessandra N, Nevena S, Tolino E, Colapietra D, Claudio M, Concetta P. Management of psoriatic patients in biologic treatment associated with infectious comorbidities. Postepy Dermatol Alergol 2020;37:417-21. [PMID: 32792886 DOI: 10.5114/ada.2020.96155] [Reference Citation Analysis]
40 Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World J Gastroenterol 2014; 20(40): 14581-14588 [PMID: 25356022 DOI: 10.3748/wjg.v20.i40.14581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
41 Fang J, Li W, Tan M, Chen W, Zhang C, Wang W, Xu Q, Guo X. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. Int Urol Nephrol 2018;50:1653-60. [PMID: 29644524 DOI: 10.1007/s11255-018-1867-0] [Reference Citation Analysis]